Study of Efficacy and Safety of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis
Recruiting
Study RIN-PF-301 is designed to evaluate the superiority of inhaled treprostinil against placebo for the change in absolute forced vital capacity (FVC) from baseline to Week 52.
Gender:
All
Ages:
40 years and above
Trial Updated:
11/29/2023
Locations: University of Minnesota, Minneapolis, Minnesota +1 locations
Conditions: Idiopathic Pulmonary Fibrosis, Interstitial Lung Disease
Idiopathic Pulmonary Fibrosis and Interstitial Lung Disease Prospective Outcomes Registry
Recruiting
This registry will collect data on the strategies used to achieve a diagnosis of Idiopathic Pulmonary Fibrosis (IPF) and Chronic Fibrosing Interstitial Lung Disease with Progressive Phenotype (ILD) and the treatment and management efforts applied throughout study follow-up, clinical outcome events and patient reported outcome data. Blood samples will be collected periodically throughout the study for use in future research efforts. For participants with non-IPF, chronic fibrosing ILD with progre... Read More
Gender:
All
Ages:
30 years and above
Trial Updated:
11/24/2023
Locations: University of Minnesota, Minneapolis, Minnesota
Conditions: Idiopathic Pulmonary Fibrosis, Interstitial Lung Disease
Efficacy and Safety Study of Orvepitant for Chronic Cough in Patients With Idiopathic Pulmonary Fibrosis
Recruiting
ORV-PF-01 is a two way, placebo controlled, cross-over study, to evaluate the effect of two doses of orvepitant on cough in patients with IPF.
Gender:
All
Ages:
40 years and above
Trial Updated:
11/15/2023
Locations: Mayo Clinic, Rochester, Minnesota
Conditions: Cough, Idiopathic Pulmonary Fibrosis
Study of TTI-101 in Participants With Idiopathic Pulmonary Fibrosis
Recruiting
The primary objective of this study is to evaluate the safety and tolerability of oral daily administration of TTI-101 over a 12-week treatment duration in participants with idiopathic pulmonary fibrosis (IPF).
Gender:
All
Ages:
40 years and above
Trial Updated:
10/19/2023
Locations: Minnesota Lung Center, Minneapolis, Minnesota
Conditions: Idiopathic Pulmonary Fibrosis
Prospective Treatment Efficacy in IPF Using Genotype for Nac Selection (PRECISIONS) Trial
Recruiting
The purpose of this study is to compare the effect of n-acetylcysteine (NAC) plus standard care with matched placebo plus standard of care in patients diagnosed with idiopathic pulmonary fibrosis (IPF) who have the TOLLIP rs3750920 TT genotype. The study will compare the time to a composite endpoint of relative decline in lung function [10% relative decline in forced vital capacity (FVC), first respiratory hospitalization, lung transplantation, or all-cause mortality] The secondary objectives w... Read More
Gender:
All
Ages:
40 years and above
Trial Updated:
03/21/2023
Locations: University of Minnesota, Minneapolis, Minnesota +1 locations
Conditions: Idiopathic Pulmonary Fibrosis